Dendreon Corporation - Fighting Cancer

Consider this micro cap insteadDon’t look now, but biotech darling Dendreon Corp. (NASDAQ: DNDN, Stock Forum) is sucking wind. The stock had surged 119% this year on the prospect of receiving FDA approval for its novel prostate cancer treatment, Provenge. But since ...

WHAT'S HAPPENING: Medicare will spend a year deciding whether to cover Dendreon Corp.'s prostate cancer therapy Provenge, which costs $93,000 for a course of treatment. WHO WOULD BENEFIT: Studies have shown Provenge adds four months to the lives of men with advanced ...

Novel drug for prostate cancer rallies body's immune system against tumorsA first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval Thursday, offering an important alternative to more taxing treatments like chemotherapy. Dendreon Corp.'s Provenge ...

FDA approved Dendreon's Provenge drug to stimulate immune system against prostate cancerThe Food and Drug Administration has approved a first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease, offering an important alternative to decades-old approaches. Dendreon Corp.'s ...

Dendreon's potential prostate cancer treatment Provenge gets May 1 FDA review dateBiotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. The drug is aimed at ...

At Last - A Non Toxic and Non Invasive Cancer Solution Backed by the FDA By King J. For If you are a prostate or other types of cancer sufferer and you dread those toxic and invasive cancer treatment solutions, perhaps it's ...

An experimental treatment added four months to the lives of men with advanced prostate cancer in a study that tested an entirely new approach to fighting the disease, doctors reported Tuesday. Dendreon Corp.'s Provenge vaccine trains the immune system to fight tumors. ...

Topic: Dendreon Corporation

Danger ahead for Dendreon (DNDN)?

Summary Box: Medicare reviews Dendreon's Provenge

FDA approves breakthrough cancer therapy Provenge

FDA approves Dendreon's cancer drug Provenge

Dendreon's Provenge gets FDA review date

At Last - A Non Toxic and Non Invasive Cancer Solution Backed by the FDA

Prostate cancer vaccine extends survival in study

From Around the Web

Video Gallery

Follow this Topic with...